Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MOK drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MOK Recombinant Protein (Kinase Domain / Full Length) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for kinase assays and SPR. |
View MOK Products |
| Gene Delivery | MOK Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and signaling pathway analysis. |
View MOK Products |
| Benchmark Ab | Anti-MOK Recombinant Antibody High-affinity positive control for Western Blot, IHC, and Flow Cytometry. |
View MOK Products |
| Validator | MOK siRNA Set Target-specific knockdown verification in tumor and intestinal epithelial cell lines. |
View MOK Products |
| Related Target A | MAPK1 (ERK2) Crosstalk kinase in the MAPK superfamily; essential for selectivity profiling. |
View MAPK1 Products |
| Related Target B | STK31 Co-expressed serine/threonine kinase implicated in cancer-testis antigen signaling. |
View STK31 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity profiling against MAPK family homologs | Recombinant MOK and closely related MAPK family proteins strictly verified by Mass Spectrometry. |
| Kinase-dead control requirement | Custom mutant recombinant proteins (e.g., kinase-dead variants) designed with sequence verification. |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies included in the catalog. |
| False Positives in phenotypic assays | Validated siRNA sets included for orthogonal target knockdown verification. |
Live MOK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MOK (MAPK/MAK/MRK overlapping kinase, also known as RAGE-1) therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum kinase inhibitors to highly selective small molecules and PROTACs. As first-generation therapies reach preclinical validation, the next wave of R&D is targeting MOK-mediated drug resistance in colorectal and renal cell carcinomas, as well as its mucosal barrier-regulatory functions in inflammatory bowel disease (IBD).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups | Renal Cell Carcinoma, Colorectal Cancer | Selectivity Assay (Need Mutant vs WT Proteins to verify ATP-pocket binding) |
| PROTAC / Degraders | Targeted Protein Degradation Pioneers | Refractory Solid Tumors | Ubiquitination & Binding Assays (Need high-purity full-length MOK protein) |
| RNA Therapeutics / siRNA | RNAi Therapeutics Developers | Inflammatory Bowel Disease (IBD) | In vitro Knockdown Validation (Need validated siRNA sets and Lentivirus) |